#China #Beijing #LakeShore Biopharma #acquisition proposal #Oceapine Capital

LakeShore Biopharma's Acquisition Proposal Overview

LakeShore Biopharma Co., Ltd., publicly traded on Nasdaq under the symbol LSB, has recently taken a significant step following the receipt of a revised preliminary non-binding acquisition proposal. This proposal, dated August 26, 2025, comes from a consortium led by Oceanpine Investment Fund II LP and Oceanpine Capital Inc., along with Crystal Peak Investment Inc. The contents of the proposal have not altered the original offer, which stands at $0.86 per Ordinary Share, a rate that has remained constant since the initial offer was made on August 18, 2025.

Consortium Composition and Shareholder Agreement

As part of the acquisition plan, the consortium currently holds approximately 52.1% of LakeShore Biopharma's outstanding Ordinary Shares. This substantial shareholding reflects their control over a notable portion of voting power within the company. Following the formation of a consortium agreement, members have committed to support the proposed acquisition and refrain from entertaining alternative bids or selling their shares until a resolution is reached.

Formation of the Special Committee

In response to receiving the revised proposal, LakeShore Biopharma's Board of Directors has moved to create a special committee of three independent directors—Adam Zhao, Thomas Xue, and Chunyang Shao. This committee will be tasked with thoroughly assessing the proposal and advising the board on how to proceed. Mr. Adam Zhao has been appointed as the committee chair, ensuring an objective evaluation process free from conflicts of interest stemming from any affiliations with the consortium.

Important Considerations for Shareholders

LakeShore Biopharma has reminded its shareholders about the importance of temperance and caution concerning their investments. The Board has clarified that it is still evaluating the proposal and no decisions have been finalized. Thus, the outcome of this process remains uncertain, with no guarantees of a definitive offer being accepted or any formal agreements established in the near future. Investors are encouraged to stay informed and refrain from hasty trading decisions based on the ongoing discussions.

Company Background

Previously known as YS Biopharma, LakeShore Biopharma remains dedicated to challenging infectious diseases and cancer through vaccine and therapeutic biologic development. With advanced technologies like their proprietary PIKA® platform, the company is actively making strides in the biopharmaceutical landscape. Operating in key markets such as China, Singapore, and the Philippines, LakeShore's leadership combines extensive industry knowledge and local expertise.

For further information, interested parties can visit their investor relations page, where updates will be posted as the situation evolves. The management team stresses that while they will facilitate shareholder discussions, they are under no obligation to keep the market informed on every development pertaining to the proposal beyond regulatory requirements.

Cautionary Note on Forward-Looking Statements

It's essential to recognize that forward-looking statements and projections are part and parcel of the current discourse surrounding the proposal. The management emphasizes that any such statements are subject to various risks and uncertainties, which could result in different actual future outcomes from those anticipated in the progressive discussions. As a result, stakeholders are advised to view any announcements with careful consideration, understanding that the situation can change rapidly.

Concluding this assessment, LakeShore Biopharma is at a pivotal juncture, and as negotiations progress, they will remain vigilant in communicating to investors and the market at large.